Skip to main content
. 2021 Nov 13;6(6):100303. doi: 10.1016/j.esmoop.2021.100303

Figure 4.

Figure 4

Sensitivity analyses—cost-effectiveness acceptability curves.

These curves summarize information on uncertainty in cost-effectiveness estimates for nivolumab, pembrolizumab, and dabrafenib-trametinib. For patients with resected high-risk stage III melanoma, the willingness to pay (WTP) threshold is €50 000. ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.